Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Nature Communications
|
November 15, 2018
A web server for comparative analysis of single-cell RNA-seq data
Amir Alavi, Matthew Ruffalo, Aiyappa Parvangada, et al.
Antiviral Research
|
February 7, 2021
Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir
Ross Martin, Jiani Li, Aiyappa Parvangada, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
September 19, 2024
Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People With HIV-1 Suppressed by Antiretroviral Therapy
Lisa Selzer, Laurie A VanderVeen, Aiyappa Parvangada, et al.
Antiviral Research
|
August 9, 2019
Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naïve subjects
Bin Han, Ross Martin, Simin Xu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
July 24, 2020
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance
Rima K Acosta, Madeleine Willkom, Kristen Andreatta, et al.
Journal of Medical Virology
|
October 7, 2024
High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre-existing HIV resistance and suboptimal adherence
Kristen Andreatta, Michelle L D'Antoni, Silvia Chang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 20, 2024
Reinfection and resistance associated substitutions following a minimal monitoring approach for HCV treatment in MINMON trial
Win Min Han, Sunil Solomon, Laura Smeaton, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
August 16, 2021
Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials
Brian Moldt, Aiyappa Parvangada, Ross Martin, et al.
AIDS (London, England)
|
February 28, 2024
HIV-1 envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infection
Laurie A VanderVeen, Lisa Selzer, Brian Moldt, et al.
AIDS (London, England)
|
September 29, 2021
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals
Brian Moldt, Huldrych F Günthard, Kimberly A Workowski, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Nature Communications
|
November 15, 2018
A web server for comparative analysis of single-cell RNA-seq data
Amir Alavi, Matthew Ruffalo, Aiyappa Parvangada, et al.
Antiviral Research
|
February 7, 2021
Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir
Ross Martin, Jiani Li, Aiyappa Parvangada, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
September 19, 2024
Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People With HIV-1 Suppressed by Antiretroviral Therapy
Lisa Selzer, Laurie A VanderVeen, Aiyappa Parvangada, et al.
Antiviral Research
|
August 9, 2019
Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naïve subjects
Bin Han, Ross Martin, Simin Xu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
July 24, 2020
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance
Rima K Acosta, Madeleine Willkom, Kristen Andreatta, et al.
Journal of Medical Virology
|
October 7, 2024
High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre-existing HIV resistance and suboptimal adherence
Kristen Andreatta, Michelle L D'Antoni, Silvia Chang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 20, 2024
Reinfection and resistance associated substitutions following a minimal monitoring approach for HCV treatment in MINMON trial
Win Min Han, Sunil Solomon, Laura Smeaton, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
August 16, 2021
Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials
Brian Moldt, Aiyappa Parvangada, Ross Martin, et al.
AIDS (London, England)
|
February 28, 2024
HIV-1 envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infection
Laurie A VanderVeen, Lisa Selzer, Brian Moldt, et al.
AIDS (London, England)
|
September 29, 2021
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals
Brian Moldt, Huldrych F Günthard, Kimberly A Workowski, et al.
Page
of 2